“Antibiotice has a business plan for 2020-2030. Over the next five years, our business plan includes about EUR200 million investments. The main source of funding comes from our profit, we are also accessing non-repayable funds. To ensure cash flow, we have a steady, long-term partnership with EIB. In 2025-2030, the management of the company is considering issuing bonds on the capital market as a new source of funding,” Liviu Vatavu said at the ZF Capital Market Summit 2025.
(English version by Loredana Fratila-Cristescu)